Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aspartate decarboxylase PanD is an essential enzyme in *Mycobacterium tuberculosis* responsible for the decarboxylation of L-aspartate to β-alanine, a critical step in the biosynthesis of coenzyme A. Pyrazinoic acid, the active metabolite of the anti-tuberculosis prodrug pyrazinamide, exerts its bactericidal effect by binding to PanD and inducing its degradation by the mycobacterial ClpC1–ClpP protease complex, leading to disruption of coenzyme A biosynthesis and subsequent bacterial death. Additionally, pyrazinoic acid acts as a protonophore, dissipating the proton motive force and disturbing cellular energetics, contributing to its killing effect. Resistance arises from mutations in panD or in the activating enzyme pyrazinamidase (pncA)[1][3][5][6][7][8][9].
Pyrazinamide is a prodrug converted by mycobacterial pyrazinamidase to pyrazinoic acid, which binds to and disrupts PanD, leading to its degradation and inhibition of coenzyme A biosynthesis[1][3][5][9]. Pyrazinoic acid also acts as a protonophore, disrupting membrane energetics and proton motive force, which impairs cellular metabolism[6][7][8].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aspartate decarboxylase PanD (PanD).